The time course of events involving inhibitor interaction with the ATP-binding pocket of HSPC1 and consequent release and degradation of the HSPC1 client (Blagg and Kerr 2006) is unclear and will undoubtedly differ between cancer cell types and between inhibitors. The gene discussed is HSP90AA1; the disease is cancer.